TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02169453

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIA 9-1067
Description: OPC, Opicapone

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIA 9-1067
Description: OPC, Opicapone

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIA 9-1067
Description: OPC, Opicapone

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIA 9-1067
Description: OPC, Opicapone

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: PLC, Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: PLC, Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: PLC, Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: PLC, Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sinemet® CR 100/25
Description: Controlled-release levodopa/carbidopa 100/25 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sinemet® CR 100/25
Description: Controlled-release levodopa/carbidopa 100/25 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sinemet® CR 100/25
Description: Controlled-release levodopa/carbidopa 100/25 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sinemet® CR 100/25
Description: Controlled-release levodopa/carbidopa 100/25 mg
Study: NCT04143074

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: multidisciplinary behavioral intervention
Description: behavioral intervention - 4 visits with each of the specialist team (pediatrician, dietician, psychologist, physical activity specialist), (4 visits x 4 specialists). Each specialist ap. 30 min time. Wisits in 0-3m-6m-12m time frame. Visits focused on behavioral intervention - motivation for change and basic tools (dietician, physical activity specialist, psychologist) to implement change in nutrition and physical activity based on individual reediness for change (based on Prochaska model).
Study: NCT00562133

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin Glulisine
Description: 100 IU/ml, 0.10 U/kg immediately before ingestion of a standardised liquid meal

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin
Description: 100 IU/ml, 0.10 U/kg 15 Minutes before ingestion of a standardised liquid meal
Study: NCT02982915

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Longeveron Mesenchymal Stem Cells (LMSCs)
Description: Intravenously delivered

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Longeveron Mesenchymal Stem Cells (LMSCs)
Description: Intravenously delivered

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Longeveron Mesenchymal Stem Cells (LMSCs)
Description: Intravenously delivered

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Fluzone High Dose Vaccine
Description: Intramuscular injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Fluzone High Dose Vaccine
Description: Intramuscular injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Fluzone High Dose Vaccine
Description: Intramuscular injection
Study: NCT04473430

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Dexcom real-time G6 Continuous Glucose Monitoring System (CGM)
Description: Dexcom G6, a factory-calibrated CGM system, is innovative in many aspects: 1) it does not require finger stick POC BG for calibration, 2) the sensor is small, compact, light-weight, 3) has no interference with several substance and drugs, and 4) protective urgent low soon alarm, with proven prediction of hypoglycemia within 20 minutes in advance. The sensor uses a novel semi-permeable membrane that blocks interference with most clinically relevant substances, including high levels of urea and creatinine, and commonly used medications. Dexcom G6 CGM is a commercially-available, minimally invasive sensor, with a flexible and thin wire that is inserted into the abdominal subcutaneous tissue. Dexcom G6 monitors glucose continuously (24 hrs) and displays real-time glucose values, glucose trends/arrows and alarms, including the urgent low soon alarm (predictive of hypoglycemia \< 55 mg/dL within the preceding 20 minutes).

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Dexcom real-time G6 Continuous Glucose Monitoring System (CGM)
Description: Dexcom G6, a factory-calibrated CGM system, is innovative in many aspects: 1) it does not require finger stick POC BG for calibration, 2) the sensor is small, compact, light-weight, 3) has no interference with several substance and drugs, and 4) protective urgent low soon alarm, with proven prediction of hypoglycemia within 20 minutes in advance. The sensor uses a novel semi-permeable membrane that blocks interference with most clinically relevant substances, including high levels of urea and creatinine, and commonly used medications. Dexcom G6 CGM is a commercially-available, minimally invasive sensor, with a flexible and thin wire that is inserted into the abdominal subcutaneous tissue. Dexcom G6 monitors glucose continuously (24 hrs) and displays real-time glucose values, glucose trends/arrows and alarms, including the urgent low soon alarm (predictive of hypoglycemia \< 55 mg/dL within the preceding 20 minutes).

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: POC BG
Description: POC BG (standard of care) uses commercially-available glucose meters for blood glucose monitoring. It is approved to be used in dialysis populations.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: POC BG
Description: POC BG (standard of care) uses commercially-available glucose meters for blood glucose monitoring. It is approved to be used in dialysis populations.
Study: NCT00001984

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alemtuzumab and DSG
Description: Alemtuzumab was administered intravenously at 0.3 mg/kg/dose over 3 hr. Patients received one dose on each of days -1,+1,+3 and +5 relative to transplantation (total dose 1.2 mg/kg). Methylprednisolone was given prior to each dose to limit the cytokine release: 500 mg prior to dose 1, 125 mg prior to dose 2, and 60 mg prior to doses 3 and 4. Deoxyspergualin was dosed as follows. The first two patients received 4 mg/kg as a loading dose on the day of transplant and 2.5 mg/kg daily for 13 additional days (14 days of treatment; 36.5 mg/kg total dose). The next three patients received the same dosing regimen but it was initiated on postoperative day 12 to coincide with the resurgence of monocytes on days 12- 25.
Study: NCT02966951

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Adipose tissue derived mesenchymal stem cell
Description: Intra-articular adipose tissue derived mesenchymal stem cell injection.
Study: NCT05748054

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Silver Diamine Fluoride
Description: A colourless solution known with its alkaline nature; it simply consists of a union of silver, fluoride and ammonia. It can be applied on caries cavities using a micro-brush.
Study: NCT02802098

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: Durvalumab is an investigational human monoclonal antibody directed against programmed death ligand-1 (PD-L1). PD-L1 can be expressed by tumours to evade detection by the immune system through binding to PD-1 on cytotoxic T lymphocytes. Durvalumab blocks the PD-L1 interaction with PD-1, countering the tumour's immune-evading tactics.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Bevacizumab is a recombinant humanized monoclonal antibody that blocks angiogenesis by inhibiting vascular endothelial growth factor A (VEGF-A)
Study: NCT02271425

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Evacetrapib Tablet
Description: Oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Evacetrapib Intravenous
Description: Intravenous administration
Study: NCT01190137

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Cholecalciferol (D3) or ergocalciferol (D2)
Description: 400 IU administered as 1 drop daily for 3 months

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Cholecalciferol (D3) or ergocalciferol (D2)
Description: 400 IU administered as 1 drop daily for 3 months
Study: NCT04094025

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dATS
Description: d-Amphetamine Transdermal System
Study: NCT02464033

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GAD-Alum
Description: Recombinant Human Glutamic Acid Decarboxylase (rhGAD65)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin D

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etanercept
Study: NCT05225350

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Dietary Intervention
Description: See previous text~Dietary intervention consisiting och each family recieving foodpackages for 5 dinner meals during three months.
Study: NCT03218241

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PRT064445
Description: Intravenous

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PRT064445
Description: Intravenous

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PRT064445
Description: Intravenous

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PRT064445
Description: Intravenous

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PRT064445
Description: Intravenous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Intravenous to mimic PRT064445

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Intravenous to mimic PRT064445

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Intravenous to mimic PRT064445

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Intravenous to mimic PRT064445

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Intravenous to mimic PRT064445
Study: NCT00597441

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Thymic Transplantation for Recipients of UCB transplant
Description: Subjects with hematologic malignancies or bone marrow failure disorders will undergo umbilical cord blood transplantation and two months post transplant will have thymic tissue from a third party donor transplanted into the thigh muscle.
Study: NCT00028743

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: carboplatin
Description: Arm 1 = 4 cycles vs Arm 2 = 8 cycles AUC5 (30 mins) day 1 of 21 day cycle

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: carboplatin
Description: Arm 1 = 4 cycles vs Arm 2 = 8 cycles AUC5 (30 mins) day 1 of 21 day cycle

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: cisplatin
Description: 4 cycles 50mg/m2 (60 mins) day 1 of 21 day cycle

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: paclitaxel
Description: Arm 1 = 4 cycles vs Arm 2 = 8 cycles 175mg/m2 (3 hours) day 1 of 21 day cycle

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: paclitaxel
Description: Arm 1 = 4 cycles vs Arm 2 = 8 cycles 175mg/m2 (3 hours) day 1 of 21 day cycle

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: topotecan hydrochloride
Description: 4 cycles~.75mg/m2 (30 mins) days 1-5 of 21 day cycle
Study: NCT02146651

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BioChaperone insulin lispro 0.2U/Kg
Description: Single dose of 0.2U/Kg body weight injected subcutaneously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BioChaperone insulin lispro 0.2U/Kg
Description: Single dose of 0.2U/Kg body weight injected subcutaneously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BioChaperone insulin lispro 0.2U/Kg
Description: Single dose of 0.2U/Kg body weight injected subcutaneously

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BioChaperone insulin lispro 0.2U/Kg
Description: Single dose of 0.2U/Kg body weight injected subcutaneously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BioChaperone insulin lispro 0.1U/Kg
Description: Single dose of 0.1U/Kg body weight injected subcutaneously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BioChaperone insulin lispro 0.1U/Kg
Description: Single dose of 0.1U/Kg body weight injected subcutaneously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BioChaperone insulin lispro 0.1U/Kg
Description: Single dose of 0.1U/Kg body weight injected subcutaneously

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BioChaperone insulin lispro 0.1U/Kg
Description: Single dose of 0.1U/Kg body weight injected subcutaneously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BioChaperone insulin lispro 0.4U/Kg
Description: Single dose of 0.4U/Kg body weight injected subcutaneously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BioChaperone insulin lispro 0.4U/Kg
Description: Single dose of 0.4U/Kg body weight injected subcutaneously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BioChaperone insulin lispro 0.4U/Kg
Description: Single dose of 0.4U/Kg body weight injected subcutaneously

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BioChaperone insulin lispro 0.4U/Kg
Description: Single dose of 0.4U/Kg body weight injected subcutaneously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Humalog®
Description: Single dose of 0.2U/Kg body weight injected subcutaneously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Humalog®
Description: Single dose of 0.2U/Kg body weight injected subcutaneously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Humalog®
Description: Single dose of 0.2U/Kg body weight injected subcutaneously

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Humalog®
Description: Single dose of 0.2U/Kg body weight injected subcutaneously
Study: NCT06236282

Intervention type: DEVICE
Intervention: ArtiSential®
Description: Articulated laparoscopic device made by Livsmed Co, South Korea.
Study: NCT05863858

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sequential Regimen: Levofloxacin 500 mg BID, Amoxicillin 1 gm BID, omeprazole 20 mg BID for first five days followed by Levofloxacin 500 mgBID, Tinidazole 500 mg BID, Omeprazole 20 mg BID
Description: The eradication rate of H. Pylori with levofloxacin-based sequential therapy

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Triple Regimen: Moxifloxacin 400mg OD, Amoxicillin 1 gm BID, Omeprazole 20mgBID
Description: The eradication rate of H. Pylori with moxifloxacin-based triple therapy
Study: NCT01520493

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Submaximal exercises
Description: Consists of a 3-min unloaded exercise, followed by a progressive RAMP protocol (10 watts/min) up to 70% of peak workload followed by 3 min. of cycling at constant workload (70% peak workload) (total exercise duration of 25 min.).
Study: NCT02540057

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Flexor carpi radialis
Description: Ligament reconstruction with tendon interposition completed using the flexor carpi radialis tendon

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Abductor pollicis longus
Description: Ligament reconstruction with tendon interposition completed using the abductor pollicis longus tendon
Study: NCT03885830

Intervention type: DRUG
Intervention: Bosutinib
Description: Subjects will be enrolled into this group if they are receiving bosutinib per standard of care. This is an observational study and no interventions will be made.

Intervention type: DRUG
Intervention: Dasatinib
Description: Subjects will be enrolled into this group if they are receiving dasatinib per standard of care. This is an observational study and no interventions will be made.

Intervention type: DRUG
Intervention: Imatinib
Description: Subjects will be enrolled into this group if they are receiving imatinib per standard of care. This is an observational study and no interventions will be made.

Intervention type: DRUG
Intervention: Nilotinib
Description: Subjects will be enrolled into this group if they are receiving nilotinib per standard of care. This is an observational study and no interventions will be made.
Study: NCT03275753

Intervention type: OTHER
Intervention: Visual Function Tests
Description: All subjects will undergo a battery of visual function tests

Intervention type: OTHER
Intervention: Visual Function Tests
Description: All subjects will undergo a battery of visual function tests

Intervention type: OTHER
Intervention: Visual Function Tests
Description: All subjects will undergo a battery of visual function tests

Intervention type: OTHER
Intervention: Visual Function Tests
Description: All subjects will undergo a battery of visual function tests
Study: NCT02949505

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Home prehabilitation program
Description: 12-week exercise therapy using daily step program (accelerometer), functional resistance exercise sessions and telephone/virtual clinic appointments
Study: NCT03589092

Intervention type: GENETIC
Intervention: Next generation sequencing (NGS)
Description: NGS Panel, Whole exome/genome sequencing

Intervention type: GENETIC
Intervention: Next generation sequencing (NGS)
Description: NGS Panel, Whole exome/genome sequencing
Study: NCT02757859

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Pancreatectomy
Description: Undergo pancreaticoduodenectomy, distal pancreatectomy, or total pancreatectomy

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Lavage
Description: Receive EIPL-S

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Pancreatectomy
Description: Undergo pancreaticoduodenectomy, distal pancreatectomy, or total pancreatectomy

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Lavage
Description: Receive EIPL-D

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Pancreatectomy
Description: Undergo pancreaticoduodenectomy, distal pancreatectomy, or total pancreatectomy
Study: NCT01401192

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine plus cisplatin
Description: Gemcitabine 1000mg/m2 D1, D8 \& cisplatin 70mg/m2 D1 every 3 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: pemetrexed plus cisplatin
Description: Pemetrexed 500mg/m2 \& cisplatin 70mg/m2 D1 every 3 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: pemetrexed plus cisplatin
Description: pemetrexed 500mg/m2 \& cisplatin 70mg/m2 every 3 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine plus cisplatin
Description: Gemcitabine 1000mg/m2 D1, D8 \& cisplatin 70mg/m2 D1 every 3 weeks
Study: NCT00116727

Intervention type: DRUG
Intervention: ENBREL®
Description: 50 mg/wk SC
Study: NCT03113903

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Psychophysical exploration
Description: Psychophysical exploration (multimodal sensitivity, including pain sensitivity) Electronic von Frey applied on forearm; thermal heat applied on forearm; foot immersion in 2°C cold water; exposure to a one-frequency noise up to uncomfortable loudness ; exposure to a halogen-lamp-generated light up to uncomfortable brightness.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Psychophysical exploration
Description: Psychophysical exploration (multimodal sensitivity, including pain sensitivity) Electronic von Frey applied on forearm; thermal heat applied on forearm; foot immersion in 2°C cold water; exposure to a one-frequency noise up to uncomfortable loudness ; exposure to a halogen-lamp-generated light up to uncomfortable brightness.
Study: NCT06158685

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Study Group
Description: Treatment: Hyperextension exercises as described by McKenzie (in addition to the conventional physiotherapy program)~McKenzie Hyperextension Exercises:~* Exercises:~  1. Prone position, arms by the side, deep breath, relax back muscles, holding for 2-3 minutes.~ 2. Prone position, raise trunk by raising head above forearms, elbows at shoulder level, maintaining for 2-3 minutes (10 repetitions).~ 3. Prone position, hands at elbow level, straighten elbows, raise the upper body from the floor and backwards as far as pain permits, holding for 2-3 seconds (10 repetitions).~ 4. Standing with feet shoulder-width apart, hands on waist, leaning backwards as far as possible from the lumbar region without bending knees, holding for 2-3 seconds (10 repetitions).~     Additional Information:~* Researcher Consistency: All treatments and evaluations were performed by the same researcher.~Frequency: 5 days a week Duration: 3 consecutive weeks

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control Group
Description: Treatment: Conventional physiotherapy program~* Components:~  * Hot pack was applied to the lumbar region for 20 minutes~ * Ultrasound (ITO device) at 1 MHz and 1.5 W/cm2 for 5 minutes~ * Transcutaneous Electrical Nerve Stimulation (TENS) at 50-100 Hz for 20 minutes~ * Researcher Consistency: All treatments and evaluations for both groups were performed by the same researcher.~* Session Duration: An average of 45 minutes per session~* Frequency: 5 days a week~* Duration: 3 consecutive weeks~* Total Sessions: 15
Study: NCT04780347

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Albumin-bound paclitaxel plus capecitabine
Description: Albumin-bound paclitaxel plus capecitabine: Albumin-bound paclitaxel 260mg/m2, IV , D1, q3w； capecitabine 1000 mg/m2, PO，bid, D1-14,q3w.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: capecitabine
Description: capecitabine: capecitabine 1000 mg/m2, PO，bid, D1-14,q3w.
Study: NCT02294916

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AWS
Description: Video-laryngoscopy 1

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AWS
Description: Video-laryngoscopy 1

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Intubrite
Description: Video-laryngoscopy 2

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Intubrite
Description: Video-laryngoscopy 2

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AirTraq
Description: Optical-laryngoscopy

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AirTraq
Description: Optical-laryngoscopy

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MIL
Description: Direct-laryngoscopy

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MIL
Description: Direct-laryngoscopy
Study: NCT01207037

Intervention type: PROCEDURE
Group type: OTHER
Intervention: blood samples and scintigraphy
Description: at 3 months, 6 months, 12 months, 18 months and 24 months will allow a clinical evaluation and an additional sampling of blood of 5 mL at each visit Scintigraphy at 6 months and 18 months
Study: NCT00004145

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: anti-thymocyte globulin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fludarabine phosphate

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: peripheral blood stem cell transplantation